Investors

Webcast ImageWebcast
Depomed at the 2016 UBS Global Healthcare Conference (Replay)
05/23/16 at 9:00 a.m. ET
Webcast ImageWebcast
Depomed at the Bank of America Merrill Lynch 2016 Health Care Conference  (Replay)
05/10/16 at 8:40 a.m. PT
Webcast ImageWebcast
Q1 2016 Depomed Earnings Conference Call (Replay)
05/05/16 at 4:30 p.m. ET

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA®ER, NUCYNTA®, Gralise®, Cambia®, Lazanda® and Zipsor®. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential.Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform®, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed’s products:

NUCYNTA® ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

NUCYNTA® (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, 

Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for Gralise and the black box warnings for NUCYNTA ER, NUCYNTA, Cambia, Lazanda and Zipsor.

Recent News> MORE
DateTitle 
05/26/16Depomed Issues Statement in Response to Starboard’s Press ReleasePrinter Friendly Version
05/23/16Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory ProfilePrinter Friendly Version
05/18/16Depomed Announces District Court Order Extending Stay in NUCYNTA ANDA LitigationPrinter Friendly Version
Upcoming and Recent Events> MORE
DateTitle
05/23/16
9:00 a.m. ET
Depomed at the 2016 UBS Global Healthcare Conference
LocationNew York, NY
05/18/16
11:00 a.m. PT
Depomed Annual Shareholder Meeting
Location7999 Gateway Blvd., Suite 300
Newark, CA 94560
05/10/16
8:40 a.m. PT
Depomed at the Bank of America Merrill Lynch 2016 Health Care Conference
LocationLas Vegas, NV

DEPO (Common Stock)

Exchange
NASDAQ CM
Price
$20.01
Change (%)
 + 0.04 (0.20%)
Volume
1,150,827
Market Cap
$1,222,569,559

Data as of 05/26/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.